Suppr超能文献

格列吡嗪与聚丙烯酸树脂RS-100共混纳米粒的制备、优化及体外评价

Preparation, Optimization and In vitro Evaluation of Glipizide Nanoparticles Integrated with Eudragit RS-100.

作者信息

Saharan P, Bahmani K, Saharan S P

机构信息

Department of Pharmaceutical Sciences, Faculty of Pharmacy, Guru Jambheshwar University of Science & Technology, Hisar, Haryana-125001, India.

Department of Pharmaceutical Sciences, Faculty of Pharmacy, Ch. Bansi Lal University, Bhiwani, Haryana, India.

出版信息

Pharm Nanotechnol. 2019;7(1):72-85. doi: 10.2174/2211738507666190319124513.

Abstract

BACKGROUND

Solubility is an important criterion for drug efficacy, independent of the route of administration. It also poses a major challenge for pharmaceutical industries, which are developing new pharmaceutical products, since 40% of the active substances being identified are either insoluble or poorly soluble in aqueous media.

OBJECTIVE

The objective of this study was to develop nanoformulation of glipizide drugloaded nanoparticles providing controlled release formulation.

METHOD

Nanoparticles were prepared by the solvent evaporation method. Eudragit RS100, a nonbiodegradable polymer with varying ratios was used for making the formulation. The effect of key formulation variables on the particle size and entrapment efficiency and drug loading of nanoparticles were studied by using factorial design.

RESULTS

DSC thermograms indicate that glipizide was dispersed in an amorphous state in the polymer. TEM study indicates that the nanoparticles were in spherical shape. The mean diameter was dependent on the presence of the amount of Eudragit RS100 and viscosity of the organic phase. The in vitro study showed that the cumulative drug release was from 69.52-81.44 % in 10 hrs at pH 6.8 in phosphate buffer respectively.

CONCLUSION

The developed NPs could reduce dose frequency, decrease side effects, and improve patient compliance. Using factorial design, maximum entrapment efficiency with minimum particle size could be achieved with a few experiments.

摘要

背景

溶解度是衡量药物疗效的重要标准,与给药途径无关。它也给开发新药品的制药行业带来了重大挑战,因为已鉴定出的活性物质中有40%在水性介质中不溶或难溶。

目的

本研究的目的是开发载有格列吡嗪药物的纳米制剂,提供控释制剂。

方法

采用溶剂蒸发法制备纳米颗粒。使用不同比例的非生物可降解聚合物Eudragit RS100来制备制剂。通过析因设计研究关键制剂变量对纳米颗粒粒径、包封率和载药量的影响。

结果

差示扫描量热图表明格列吡嗪以无定形状态分散在聚合物中。透射电镜研究表明纳米颗粒呈球形。平均直径取决于Eudragit RS100的用量和有机相的粘度。体外研究表明,在pH 6.8的磷酸盐缓冲液中,10小时内累积药物释放率分别为69.52 - 81.44%。

结论

所开发的纳米颗粒可减少给药频率,降低副作用,并提高患者依从性。通过析因设计,只需进行少量实验就能实现最大包封率和最小粒径。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验